GlassScriptPhysician profile
Lalitha Koduri
NPI 1619922192
$2,359.37
in general payments reported to CMS, 2019-2025
32 companies · $640 in 2025
The $640 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $37.27 · 2021: $439 · 2022: $430 · 2023: $256 · 2024: $432 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.20 | 2020-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mylan Specialty L.P. | $255.61 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $170.73 | 2024-2025 | Dupixent |
| Vanda Pharmaceuticals INC. | $159.96 | 2021-2024 | Hetlioz, Fanapt |
| Baxter Healthcare | $133.31 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $122.94 | 2022 | |
| Philips North America LLC | $106.43 | 2022-2025 | Vest Therapy Und, (O58) Sleep Respiratory Care Und |
| Viiv Healthcare Company | $100.44 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $89.62 | 2025 | Zerbaxa |
| Glaxosmithkline, LLC. | $80.20 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Jazz Pharmaceuticals INC. | $64.34 | 2021 | |
| Inogen, INC. | $63.61 | 2025 | |
| Grifols USA, LLC | $62.88 | 2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $45.84 | 2019 | |
| Covis Pharma Gmbh | $43.06 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $41.59 | 2023-2024 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $37.84 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $34.65 | 2022-2023 | |
| Astellas Pharma US INC | $32.33 | 2024 | Cresemba |
| Melinta Therapeutics, LLC | $31.84 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.41 | 2025 | Fasenra |
| Exact Sciences Corporation | $27.05 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $26.11 | 2021 | |
| 3b Medical, INC. | $25.97 | 2025 | Luna |
| Abbvie INC. | $25.56 | 2024 | |
| Janssen Biotech, INC. | $24.43 | 2021 | |
| Axsome Therapeutics, INC. | $22.91 | 2025 | Sunosi |
| Gilead Sciences, INC. | $20.30 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.77 | 2025 | Amvuttra |
| Scilex Pharmaceuticals INC. | $15.66 | 2023 | Ztlido |
| Biomerieux INC | $15.27 | 2020 | |
| Medicomp INC | $13.51 | 2025 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lalitha Koduri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.